Home Blog Page 758

CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

By
Advertorial Desk
-

Rapid Advancement Across Core R&D Pipeline

  • The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an excellent safety profile with a ≥Grade 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity. Notably, monotherapy data in lung cancer are encouraging: in first-line NSCLC patients with PD-L1 TPS ≥50%, the ORR reached 90% with a DCR of 100%, while the ORR was 25% in IO-pretreated NSCLC (AGA-negative). Furthermore, significant benefits were observed in patients with heavily pre-treated “cold tumors,” achieving an ORR of 40% in non-clear cell renal cell carcinoma (nccRCC) and 33.3% in soft tissue sarcoma (STS).
  • The global Phase Ib multicenter trial of CS5001 (ROR1 ADC) is being advanced rapidly and efficiently in Australia and China, with its R&D progress ranking among the top two globally. In combination with R-CHOP as a first-line treatment for DLBCL (at doses of 50–90 μg/kg), the CR rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination cohort for later-line DLBCL has also shown favorable safety and a high ORR.

Continued Expansion of Global Commercialization Footprint

  • Since 2025, sugemalimab has secured two new strategic partnerships and received approvals for two additional indications. Its global commercialization footprint now spans over 60 countries and regions, with further collaborations and regulatory filings actively underway.

Breakthroughs in Local Manufacturing and Reimbursement Access

  • GAVRETO® (pralsetinib) successfully obtained approval for local manufacturing in China and was included in the National Reimbursement Drug List (NRDL) for the first time, positioning it for significant sales growth.
  • The domestic supply of AYVAKIT® (avapritinib) has officially commenced, complementing its successful NRDL renewal at the end of last year.

Emerging Preclinical Innovation Pipeline

  • Three internally developed next-generation ADC candidates—CS5007 (EGFR/HER3 ADC), CS5008 (SSTR2/DLL3 ADC), and CS5006 (ITGB4 ADC)—will present preclinical research findings at AACR 2026, with IND submissions planned for 2026.

Solid Financial Position

  • Revenue was RMB269.6 million for the year ended December 31, 2025. The revenue from sales of pralsetinib decreased substantially, which is primarily due to price adjustments of pralsetinib made in preparation for the NRDL negotiation, along with related one-off channel compensation. Upon pralsetinib’s inclusion in NRDL, the anticipated revenue ramp-up in 2026 and beyond is expected to outweigh the short-term negative impact on revenue in 2025. License fee income also decreased substantially, primarily due to the recognition of significant one-time upfront fees and milestone payments received in 2024.
  • Cash and cash equivalents and time deposits were RMB918.7 million as of December 31, 2025.

SUZHOU, China, March 26, 2026 /PRNewswire/ — CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced its 2025 annual results and recent business highlights.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, “2025 represents a pivotal strategic inflection point for CStone as we advance our Pipeline 2.0 and accelerate our commercial transformation. Over the past year, we have made highly efficient progress across our innovative pipeline, with our core asset, CS2009, demonstrating compelling efficacy in the latest clinical data. We are on track to initiate multiple global multi-regional Phase III trials by the end of 2026, reinforcing its potential as a next-generation immuno-oncology backbone.

On the commercial front, we continued to expand the global footprint of sugemalimab, while achieving important milestones in China for pralsetinib and avapritinib, including localization and reimbursement access. These efforts have reignited growth momentum in the China market and strengthened the foundation of our commercial platform.

Importantly, while driving business growth, we have maintained a solid financial position, with a cash balance of RMB 918.7 million as of the end of 2025. This financial strength enables us to continue investing in innovation while ensuring disciplined and sustainable operations.

Looking ahead, we remain committed to maximizing the commercial value of our established products while advancing our Pipeline 2.0 with focus and discipline. Through continued innovation and execution, we aim to drive long-term value creation and deliver sustainable returns for our shareholders.”

Business Highlights

For the year ended December 31, 2025, and up to the date of this results announcement, we advanced our innovative pipeline and maximized the commercial value of our in-market assets. Our Pipeline 2.0 achieved significant progress, highlighted by the clinical program CS2009 advancing to Phase II and delivering the first global clinical data for a PD-1/VEGF/CTLA-4 trispecific antibody. We also expanded our therapeutic focus into autoimmune and inflammatory diseases. Commercially, we secured two international agreements for the global commercialization of sugemalimab and obtained regulatory approvals in the European Union (EU) and United Kingdom (U.K.) for Stage III NSCLC. In China, AYVAKIT® (avapritinib) was successfully renewed on the NDRL, while GAVRETO® (pralsetinib) achieved its first-time inclusion. These accomplishments underscore our sustained commitment to developing innovative therapies for patients worldwide.

Clinical Stage Core Assets

CS2009, PD-1/VEGF/CTLA-4 trispecific antibody

  • Global Phase II trial Ongoing

Patient enrollment is active in our global, multicenter Phase II trial. The first patient was dosed in Australia in September 2025. The IND application for this trial was approved by the China National Medical Products Administration (NMPA) in November 2025 and by the U.S. Food and Drug Administration (FDA) in February 2026. This multi-cohort, parallel expansion study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK)/Pharmacodynamics (PD) of CS2009 as monotherapy and in combination regimens in 15 cohorts across 9 solid tumor indications, including NSCLC, colorectal cancer (CRC), extensive-stage small cell lung cancer (ES-SCLC), cervical cancer (CC), gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC), platinum-resistant ovarian cancer (PROC), triple-negative breast cancer (TNBC), and hepatocellular carcinoma (HCC). Active patient enrollment is ongoing in Australia and China.

  • First-in-class (FIC)/best-in-class (BIC) potential as next-generation I/O backbone

More than 100 late-line patients have been enrolled in Phase I trial. CS2009 has demonstrated a favorable safety and tolerability profile, with no dose-limiting toxicity (DLT) reported and maximum tolerated dose (MTD) not reached. As of the data cutoff of March 17, 2026 with a median follow-up of approximately 6 months. The more mature data continue to reinforce its favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs). No excessive toxicities related to CTLA-4 occurred, and the incidence of Grade ≥3 VEGF-related AEs was low.

CS2009 monotherapy demonstrates potent antitumor activity in later-line “cold” tumors that are not sensitive to PD-(L)1 mAb. An overall response rate (ORR) of 40% was observed in patients with nccRCC, and an ORR of 33.3% in STS, showcasing its broad-spectrum therapeutic potential across multiple tumor types.

Safety data from multiple cohorts of CS2009 combined with standard chemotherapy showed that the combinations were well-tolerated across tumor types, with CS2009 not increasing the incidence or severity of chemotherapy-related adverse events.

Compelling Efficacy has been observed in Lung Cancer. CS2009 monotherapy demonstrates encouraging Phase I/II efficacy in NSCLC. In first-line NSCLC (PD-L1 tumor proportion score [TPS]≥50%), the ORR reached 90%, with a DCR of 100%. In IO-pretreated, AGA negative second-/later-line NSCLC, ORR reached 25%.

  • Efficient and Clearly-Defined Global Development Strategy

Additional Phase I and Phase II clinical data for CS2009 are expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.

The company plans to initiate the first wave of Phase III global multi-regional clinical trials (MRCT) for CS2009 by the end of 2026, targeting indications including NSCLC, CRC, and ES-SCLC.

CS5001, ROR1 ADC

  • Global Phase Ib enrollment ongoing

The global, multicenter Phase Ib clinical trial of CS5001 continues to advance patient enrollment across sites in Australia and China. The trial is designed to determine the recommended Phase II dose (RP2D) and further evaluate the safety, tolerability, PK, and efficacy of CS5001 as monotherapy and in combination with systemic therapies in nine cohorts of selected tumor types. Current enrollment is prioritizing combination cohorts with standard-of-care (SOC) regimens, including CS5001 in combination with R-CHOP (Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone) for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and CS5001 in combination with other SOC therapies for front-line DLBCL. Monotherapy cohorts continue to enroll patients with aggressive and indolent advanced lymphomas. In parallel, CS5001 is being evaluated in advanced solid tumors, both as monotherapy and in combination with the anti-PD-L1 antibody sugemalimab.

  • Promising efficacy and safety profile observed in front line DLBCL

When combined with R-CHOP in the first-line DLBCL setting, no DLTs were observed across the 50–90 μg/kg dose range, with an ORR of 100% and a complete response (CR) rate exceeding 90%. In later-line DLBCL, the combination with standard-of care therapies is currently undergoing dose finding, with no DLTs reported to date and a high ORR already observed.

Commercial Products

CEJEMLY® (sugemalimab), anti-PD-L1 antibody

  • Global expansion and regulatory approvals

Following sugemalimab’s initial marketing authorization in the EU and U.K. for Stage IV NSCLC, the product received additional approvals in the EU in November 2025, and subsequently in the U.K. in February 2026, as monotherapy for adults with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemoradiotherapy (CRT). With these approvals, sugemalimab has become one of only two anti-PD-(L)1 antibodies approved in both the EU and U.K. for Stage III NSCLC, positioning it as a comprehensive therapy option spanning locally advanced, unresectable Stage III to metastatic Stage IV disease. Meanwhile, marketing authorization applications for sugemalimab have been either approved or are under active review in more than ten countries worldwide.

  • Global commercialization driven by strategic alliances

In January 2025, we entered into a partnership with Laboratorios Stein S.A. (SteinCares) to commercialize sugemalimab across ten countries in Latin America (LATAM). This was followed by a partnership with Istituto Gentili S.R.L. (Gentili) in July 2025 to commercialize sugemalimab in 23 countries in Western Europe and the U.K. To date, four partnerships have been executed extending sugemalimab’s international footprint to over 60 countries around the world. Additional partnerships in other markets are under discussion.

GAVRETO® (pralsetinib), RET inhibitor

  • Localized production approved

In July 2025, the China NMPA approved the manufacturing localization application for Pralsetinib Capsules (pralsetinib, 100 mg). In 2026, the supply in China will gradually transition from imported products to end-to-end domestic production – from active pharmaceutical ingredient to finished drug product – significantly enhancing cost efficiency and supply chain resilience.

  • NRDL inclusion

In December 2025, GAVRETO® (pralsetinib, 100 mg) was included for the first time in the latest NRDL released by China’s National Healthcare Security Administration, which took effect on January 1, 2026.

AYVAKIT® (avapritinib), KIT/PDGFRA inhibitor

  • Domestic supply launched

Following the 2024 China NMPA approval for localization production, domestic supply of avapritinib tablets (300 mg and 100 mg) commenced in February 2025, driving anticipated gross margin expansion.

  • NRDL renewal

Following its initial inclusion in December 2023, AYVAKIT® was also successfully renewed on the NRDL in December 2025.

Preclinical/IND-enabling Stage Programs and Proprietary ADC platform

CStone’s preclinical Pipeline 2.0 compromises over nine promising candidates across multispecific antibodies, antibody-drug conjugates (ADC) etc in oncology, immunology and inflammation diseases. We are dedicated to delivering clinical value through the development of these Pipeline 2.0 candidates, which will undergo international, multi-center clinical trials to maximize their global potential.

Our proprietary in-house ADC platform features optimized linkers for tumor-selective payload release and supports multiple Pipeline 2.0 ADC assets, including CS5007 (EGFR/HER3 bispecific ADC), CS5008 (DLL3/SSTR2 bispecific ADC), CS5006 (ITGB4 ADC), CS5009 (B7H3/PD-L1 bispecific ADC), etc.

In May 2025, we presented preclinical data for CS2009, CS5007, and CS5006 at the annual meeting of the American Association for Cancer Research (AACR).

Future and Outlook

Our mission is to deliver transformative therapies through scientific excellence and technological innovation, making high-quality treatments accessible worldwide to benefit patients and their families.

We reaffirm our commitment to advancing a robust and differentiated pipeline by prioritizing internal discovery capabilities and sustained R&D investments, while executing strategic partnerships to unlock the global value of our in-market products. Critical catalysts in 2026 include:

Clinical milestones

  • Accelerate the clinical development of CS2009 and CS5001 while pursuing global partnerships to expedite development.
  • Advance CS5007, CS5006, and other early-stage candidates into clinical stages.

Innovation and technology

  • Strengthen proprietary platforms (e.g., ADC technology) to bolster our early preclinical pipeline.
  • Present key clinical data at major conferences (e.g., ASCO and/or ESMO).

Financial Highlights

International Financial Reporting Standards (IFRS) Measures:

  • Revenue was RMB269.6 million for the year ended December 31, 2025. The revenue is composed of RMB78.3 million from sales of pharmaceutical products (avapritinib, pralsetinib and sugemalimab), RMB167.7 million from license fee income and RMB23.6 million from royalty income of sugemalimab. (1) Revenue from sales of pralsetinib decreased substantially, which is primarily due to price adjustments of pralsetinib made in preparation for the NRDL negotiation, along with related one-off channel compensation. With pralsetinib’s inclusion in the NRDL effective January 1, 2026, the anticipated revenue ramp-up in 2026 and beyond is expected to outweigh the short-term negative impact on revenue. (2) License fee income also decreased to some extent, primarily due to the recognition of significant one-time upfront fees and milestone payments received in 2024.
  • Cost of revenue was RMB218.3 million for the year ended December 31, 2025, primarily due to inventory write-downs charged to cost of revenue and cost associated with an early billing of pralsetinib supply under the Patient Assistance Program covering the period through the first half of 2026 to mitigate customs clearance risks amid trade uncertainties.
  • Research and development expenses were RMB311.5 million for the year ended December 31, 2025, primarily due to an increase in third party contracting costs for clinical trials, including the Phase I/II study for CS2009 and for research programs including CS5007’s IND enabling studies.
  • Administrative expenses were RMB89.0 million for the year ended December 31, 2025.
  • Selling and marketing expenses were RMB83.3 million for the year ended December 31, 2025.
  • Loss for the year was RMB437.0 million for the year ended December 31, 2025. Excluding a one-time negative impact of RMB146.9 million in total from channel compensation and inventory write-downs related to preparation for inclusion of pralsetinib in the NRDL, the loss was RMB290.1 million.
  • Cash and cash equivalents and time deposits were RMB918.7 million as of December 31, 2025.

Non-International Financial Reporting Standards (Non-IFRS) Measures:

  • Research and development expenses excluding the share-based payment expenses were RMB299.5 million for the year ended December 31, 2025, primarily due to an increase in third party contracting costs for clinical trials, including the Phase I/II study for CS2009 and for research programs including CS5007’s IND enabling studies.
  • Administrative and selling and marketing expenses excluding the share-based payment expenses were RMB160.4 million for the year ended December 31, 2025.
  • Loss for the year excluding the share-based payment expenses was RMB413.0 million for the year ended December 31, 2025. Excluding both (1)share-based payment expenses of RMB24.0 million and (2) a one-time negative impact of RMB146.9 million in total from channel compensation and inventory write-downs related to preparation for inclusion of pralsetinib in the NRDL, the loss was RMB266.1 million.

2025 Annual Results Conference Call

The Company will host its 2025 annual results earnings call at 10:00 a.m. (Beijing Time) on Friday March 27, 2026. Please register for the conference in advance through the link: https://s.comein.cn/f79etaud.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring ADCs, multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com. 

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

 

NetDragon Announces 2025 Annual Financial Results

By
Advertorial Desk
-

Cost Optimisation Delivered Notable Results with Operating Profit Up 48% YoY in H2 2025

Final Dividend of HKD0.5 Per Share, AnnoNetDuncing New Shareholder Return Program of No Less Than HKD600 Million

HONG KONG, March 26, 2026 /PRNewswire/ — NetDragon Websoft Holdings Limited (“NetDragon” or the “Company”; Hong Kong Stock Code: 0777), a global leader in building internet communities, announced its financial results for fiscal year 2025 today. NetDragon’s management team will be hosting a conference call and webcast on March 27, 2026 at 10:00am Hong Kong time, to discuss the results and recent business developments.

Dr. Dejian Liu, Chairman of NetDragon, commented: “In 2025, following our strategy to ‘Fully Embrace AI’, the Company further introduced the ‘AI Now’ strategy to fully implement our transformation. We have made encouraging progress across our core verticals of education, gaming and AI+ strategic investments across various sectors. The Company has taken initial steps of transforming into an AI organisation, advancing toward our long-term vision of becoming a global leader in AIGC. Meanwhile, we continued our operational optimisation initiatives. Our overall operating expenses for the year decreased by 22.2% YoY, while operating profit in the second half of the year increased by 47.7% YoY. We expect the benefits of cost optimisation to be further realised in 2026, laying a solid foundation for the Company’s long-term value creation.”

“In education AIGC, leveraging our AI Content Factory, we achieved multiple breakthroughs in product innovation, content creation, and AI integration, building a digital education ecosystem centered on ‘gamified learning’ and laying a strong foundation for scalable, intelligent and immersive learning experiences. Our US-listed subsidiary, Mynd.ai has reduced the segmental operating expenses by 21.1% YoY in 2025, whilst the adjusted EBITDA loss has been reduced by 61.8% QoQ in 4Q 2025. In gaming AIGC, we are actively incubating AI-native games, expanding into new genres and exploring the next-generation gaming experiences driven by AI as the core operational logic. Our flagship IP maintained solid profitability, with the core segmental profit margin of the gaming and application services reaching 27.4%, representing an increase of 3.9 percentage points YoY, whilst the profit scale remained solid. In AI+ strategic investments, we are focusing on unlocking the potential of AI computing power and AIGC production capacity. We will continue to invest in various frontier sectors such as AI and AR .”

“We have also established several significant strategic collaborations to support our long-term development. We have entered into a partnership with Volcengine, ByteDance’s cloud and AI service platform. Together, the two parties will build a deep competitive moat integrating technology, resources, and ecosystem in China’s higher education and vocational education sectors. By scaling the production of next-generation AIGC educational resources, we aim to create a globally co-created and shared innovative education ecosystem. We established a long-term cooperation with Thailand’s Ministry of Higher Education, Science, Research and Innovation (MHESI) to systematically advance an AI-driven ‘Learn-to-Career’ ecosystem in Thailand. With the support of the World Bank, we signed a cooperation agreement with Ministry of Secondary Education of Cameroon (MINESEC) to jointly promote the digital transformation of 250 schools across the country. In addition, our Hong Kong subsidiary Cherrypicks successfully secured the strategic investment from Zhongke WengAI, a leading AI enterprise in China and has repositioned as the exclusive overseas expansion platform and commercialisation partner for Zhongke WengAI in overseas markets. Supported by these strategic partners, We are well placed to accelerate our progress toward becoming a global leader in AIGC creation.”

“Our ongoing efforts in key aspects of sustainable development, such as environmental protection, social responsibility, and corporate governance, have continued to receive widespread recognition. Recently, the Company’s MSCI ESG rating was further upgraded from BBB to A, extending the strong momentum of positive achievements in ESG over the past five years. The company will continue to adhere to its long-term commitment to creating lasting and sustainable value for nature, society, and all stakeholders, including shareholders, customers, and employees.”

“Supported by the positive outcomes of our strategic investments and solid cash position, we remained committed to enhancing shareholder returns. The Board has approved a final dividend of HKD0.5 per ordinary share, bringing total dividends for the year to HKD1.0 per ordinary share. Since announcing a shareholder return program of no less than HKD600 million on 29 August 2025, we have fulfilled our commitment through dividends and share repurchases with the inclusion of the proposed final dividend. The core segmental profit from gaming and application services for the year remained solid at RMB897 million. As of December 2025, our net cash and liquid investments position remained robust at RMB2.0 billion. Based on our confidence in the Company’s long-term sustainable development, we commit to distribute a total of no less than HKD600 million to shareholders over the next 12 months through dividends and share repurchases.”

Fiscal Year 2025 Financial Highlights

  • Revenue was RMB4.5 billion, representing a 26.0% decrease YoY.
  • Revenue from gaming and application services was RMB3.3 billion, representing 73.2% of the Group’s total revenue and a 16.8% decrease YoY primarily attributable to the optimisation of flagship IP to support its long-term development and sustainability.
  • Revenue from Mynd.ai business was RMB1.2 billion, representing 26.7% of the Group’s total revenue and a 43.2% decrease YoY primarily due to the impact of disposal of Singapore early education business in the second half of 2024, and a prolonged demand adjustment cycle. Customer demand is expected to recover as market conditions stabilise.
  • Gross profit was RMB3.1 billion, representing a 20.2% decrease YoY, whereas gross profit margin increased by 5.1 percentage points YoY to 70.3% .
  • Operating expenses decreased by 22.2% YoY to RMB2.6 billion, reflecting the impact of our cost reduction and efficiency improvement measures, which are expected to be fully realised in 2026.
  • Core segmental profit[1] from gaming and application services was RMB897 million, representing a 3.0% decrease YoY, as the lower revenue was partially offset by cost savings. Core segmental profit margin increased by 3.9 percentage points YoY to 27.4%.
  • Core segmental loss[1] from Mynd.ai business was RMB358 million, compared to a loss of RMB297 million in 2024. Core segmental loss[1] for the second half of 2025 was RMB163 million, representing a 12.4% decrease YoY.
  • Profit attributable to owners of the Company was RMB151 million, representing a 51.4% decrease YoY, affected by an impairment loss of cryptocurrencies as of 31 December 2025, as well as one-off expenses associated with the staff optimisation plan.
  • The Company declared a final dividend of HKD0.50 per ordinary share (2024: HKD0.50 per ordinary share), subject to approval at the coming annual general meeting.

Segmental Financial Highlights

FY2025

FY2024

Variance

(RMB million)

Gaming and
application
services

Mynd.ai

business

Gaming and
application
services

Mynd.ai

business

Gaming and
application
services

Mynd.ai

business

Revenue

3,276

1,197

3,938

2,106

-16.8 %

-43.2 %

Gross Profit

2,852

299

3,399

547

-16.1 %

-45.3 %

Gross Margin

87.1 %

25.0 %

86.3 %

26.0 %

+0.8 ppts

-1.0 ppts

Core Segmental
Profit (Loss)[1]

897

(358)

925

(297)

-3.0 %

+20.5 %

Segmental Operating
Expenses[2]

 – Research and
   development

(820)

(193)

(1,227)

(202)

-33.2 %

-4.5 %

 – Selling and
   marketing

(406)

(251)

(488)

(266)

-16.8 %

-5.6 %

 – Administrative

(658)

(211)

(705)

(362)

-6.7 %

-41.7 %

Gaming and Application Services Business

In 2025, revenue from our gaming and application services business amounted to RMB3.3 billion, representing a decrease of 16.8% YoY. We further advanced our strategic focus in the application services business by reducing the equity interests in several subsidiaries, which contributed to the decline in segmental revenue. Segmental operating expenses for the year decreased by 22.1% YoY driven by cost savings from the AI+ strategy with the full-year impact to be realised in 2026. Core segment profit was RMB897 million, representing a decrease of 3.0% YoY only, as the lower revenue was partially offset by the benefits from cost savings for the year.

In the gaming sector, our AIGC capabilities are now delivering tangible results, reinforcing our R&D strategy to focus on AI-native games: Across our flagship evergreen IPs, we have fully leveraged our AIGC capabilities to further shift user activities toward content-driven and culture-driven spending while fostering healthier community development. We also continued to explore incremental growth through format innovation and regional expansion, alongside ongoing investments in content innovation and cultural expression.

The average monthly active users (MAU) of the Eudemons IP increased by 11.1% YoY in 2025, with an increase of 7.1% in the second half of 2025 HoH. Eudemons IP has delivered both HoH and YoY MAU growth for four consecutive half-year periods, ensuring the long-term operation of this evergreen IP and significantly narrowing the YoY decline in overall gaming revenue in the second half. Revenues from Conquer IP and Heroes Evolved IP increased by 6.4% and 21.3% YoY, respectively. Among them, Conquer IP focused on the global dissemination of Chinese martial arts culture, with overseas market revenue accounting for nearly 70% of its total revenue. Heroes Evolved IP adhered to the dual engines of content innovation and esports events, with PC revenue achieving YoY growth for three consecutive years and reaching a record high in 2025.

In 2025, under the guidance of the Fujian Provincial Department of Culture and Tourism, we launched the “Digital Mountains & Seas – Game Empowering Fujian Culture & Tourism” project in collaboration with the Xinhua News Agency and other partners. Our core gaming IPs subsequently entered into cross-sector collaborations with cultural and tourism departments in Fuzhou, Quanzhou, Wuyishan, Nanping, and other regions, deeply integrating with various world heritage, intangible cultural heritage and distinctive cultural tourism IPs. By applying a range of cutting-edge AI technologies such as digital capture and game integration, we create a new paradigm for “Gaming + Culture Tourism.”

Our “AI+Gaming” strategy has been fully implemented in our operations. In 2025, segmental R&D expenses for the gaming and application services decreased by 33.2% YoY, while the share of AI-driven workload in overall game development increased to 25%. Our AI anti-cheat features have covered multiple core gameplay scenarios of Eudemons IP, further improving the in-game environment and ecosystem health. AI companion agents have been fully applied across both Conquer IP and Heroes Evolved IP, significantly improving player retention. In addition, more than 1,000 second-generation intelligent NPCs have been deployed in the Zero IP, delivering encouraging results. We have also successfully established an initial development pathway for AI-native games and built a closed-loop system comprising AI Creative Center, AI Production Center and AI Operations Center. This has significantly reduced the production cost and development cycle of new gaming products, giving us greater resources and more time to continue iterating and experimenting with new ideas, genres and gameplay while enhancing both the scale and quality of our R&D pipeline. We plan to deploy more AI agent employees to increase the share of AI-driven workload to 50% by the end of 2026.

Looking ahead, for mature fields with fully validated business models, we will leverage our AIGC capabilities to replicate success quickly and efficiently. Furthermore, we will position AI-native games as a strategic focus, building a diversified product portfolio centered on new forms of content and user experience. In 2026, the Company plans to expand into new genres, including Match-3 and Roguelike, and will develop multiple new titles.

In the application services sector, we are sharpening our strategic focus and accelerating commercial expansion with education AIGC: Our AI Content Factory has achieved significant advances in automation and intelligence, substantially improving the production efficiency of foundational AIGC elements such as AI textbooks, AI courseware, resource granules, and interactive educational games while further reducing production costs. In the integration of “gamified learning” and “AI+Education,” we continue to make learning more emotionally engaging and immersive. We will remain committed to the core vision that “Knowledge is Experience, Learning is Gaming,” and continue to drive the digital transformation of education globally.

We have recently launched the AI Employee Matrix, fully reconstructing the entire content production chain. AI employees can autonomously handle the complete closed-loop workflow—spanning from creative ideation, intelligent image generation, material refinement to video rendering—7×24 hours without interruption. They precisely take on highly repetitive and time-sensitive tasks, enabling the rapid production of massive volumes of high-quality content. Compared with the traditional human-powered model, this approach significantly shortens production cycles, substantially reduces costs, ensures consistent quality, and enables the shift of content production from “human-driven” to “intelligence-driven”, achieving the goals of standardization, scale, and extreme speed. With the AI Employee Matrix, we are deepening human–machine collaboration, liberating productivity, allowing focus on creativity and quality enhancement, and injecting powerful new momentum of large-scale intelligent content supply into fields such as education.

Our country rollout strategy also continued to make progress. In February 2026, our strategic partnership with Thailand’s Ministry of Higher Education, Science, Research and Innovation (MHESI) was further deepened. Together, we will develop an AI-enabled learning platform, competency assessment framework, and career transition mechanism, building an AI-driven “Learn-to-Career” ecosystem that connects education, skills development and productivity enhancement, and supports Thailand in cultivating a future-ready workforce. In March 2026, the AI-enabled smart classroom jointly developed with Cameroon’s Ministry of Secondary Education (MINESEC) was successfully inaugurated in Yaoundé, the capital of Cameroon, with the Prime Minister of Cameroon and several senior government officials attending the ceremony. This project will also serve as a pilot for the scalable development of digital education across Africa.

In addition, the Company’s strategic investments in frontier technologies and AIGC sectors continue to achieve significant progress: The new-generation AI glasses launched by an AI edge device company we invested in recorded rapid sales growth. Our investee in group live-streaming content production also continued to lead the market, received strong support from the short-video platform, and jointly hosted major live performance events. Currently, we are further expanding our strategic investments and business synergies in various frontier sectors by leveraging AI computing power and AIGC creative capabilities. Looking ahead, our strategic investments will continue to focus on frontier technology such as AI and AR, as well as various cultural and creative industries that can be significantly empowered by AIGC, therefore strengthening synergies with our core business and cultivating new growth drivers for the Company’s long-term development.

Mynd.ai

Notwithstanding industry-wide customer budget uncertainties and increasing challenges of global trade, we are focused on positioning Mynd.ai for future success. We have delivered a major refresh of our flagship product with the launch of our next-generation integrated solution, ActivPanel 10® and Promethean ActivSuite® software and expanded into new product categories through the introduction of ActivPanel LE and ActivPanel D-series, as well as new software and hardware partnerships. Various cost optimisation initiatives were carried out this year to improve our competitive positioning in the market and facilitate further investments in our business.

We continue to evolve our AI-enabled solution roadmap and significantly enhance the interaction of the full ecosystem of software and hardware offerings in a classroom by consolidating cutting-edge AI solutions such as Merlyn Mind and Augment Me.

The key financial highlights for Mynd.ai in 2025 are as follows:

  • Revenue of RMB1.2 billion compared to RMB2.1 billion in the prior year, with the decrease primarily driven by elevated uncertainty amongst our customers regarding future budget allocations, which represents an industry-wide phenomenon that affected the entire education technology market. Customer demand is expected to recover as market conditions stabilise and schools look to refresh their existing technology solutions.
  • Segmental operating expenses of RMB655 million with a decrease of 21.1% YoY, as management continues to implement cost-saving measures to mitigate effects of education technology market headwinds
  • Core segmental loss of RMB358 million compared to a loss of RMB297 million in the prior year. Core segmental loss for the second half was RMB163 million, representing a 12.4% decrease YoY.

Management Conference Call and Webcast

NetDragon’s management team will hold a conference call and webcast at 10:00 am Hong Kong time on March 27, 2026 to discuss the results and recent business developments.

Details of the live conference call and webcast are as follows:

Webcast

https://webcast.roadshowchina.cn/Em83RN

International

+852 3008 3269

Mainland China                                       

HK (China)

4008 070 263

+852 3008 3269

US

+1 516 226 8028

UK

+44 20 3761 0113

Passcode

775091476#

The live and archived webcast of the conference call will be available on the Investor Relations section of NetDragon’s website at http://ir.nd.com.cn/en/category/webcast. Participants of the live webcast should visit the aforementioned website 10 minutes prior to the call, then click on the icon for “2025 Annual Results Conference Call and Webcast” and follow the registration instructions.

About NetDragon Websoft Holdings Limited

NetDragon Websoft Holdings Limited (HKSE: 777) is a global leader in building internet communities, with a long track record of developing and scaling multiple internet and mobile platforms that impact hundreds of millions of users. Over the desktop and mobile internet eras, NetDragon previously established China’s first online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless.  

Established in 1999, NetDragon is one of the most reputable and well-known online game developers in China with a history of successful game titles including Eudemons Online, Conquer Online, Heroes Evolved and Under Oath. In the past 10 years, NetDragon has also achieved success with its EdTech business both domestically and globally. Fully embracing the new AI era, NetDragon is driving its vision of “Infinite Growth” through a dual-focus strategy of “AI+Gaming” and “AI+Education”. With its AI Content Factory empowering operations and working with partners to develop a global learning metaverse, NetDragon is committed to once again building a massive user community in the new AI era.

NetDragon’s overseas edtech business entity, currently a U.S.-listed subsidiary named Mynd.ai, is a global leader in interactive technology and its award-winning interactive displays and software can be found in more than 2 million learning and training spaces across 126 countries.  

For investor enquiries, please contact:
NetDragon Websoft Holdings Limited
Email： ir@netdragon.com

[1] Core segmental profit (loss) figures are derived from the Group’s reported segmental profit (loss) figures (presented in accordance with HKFRS 8), but exclude non-core/operating, non-recurring or unallocated items including redundancy payments, interest expense and exchange difference on convertible and exchangeable bonds and convertible note, impairment loss (net of reversal), fair value loss on investment properties, impairment loss and write off of intangible assets, net gain on disposal of subsidiaries, fair value gain and exchange difference on financial assets at fair value through profit or loss, government grants, fair value gain and exchange loss on derivative financial instruments, reversal of impairment loss of inventories and intangible assets, gain on deemed disposal of an associate, intercompany finance costs, underprovision of tariff expenses in prior years, project expenses, write-down of inventories and waiver of other payables.
[2] Segmental operating expenses exclude unallocated expenses/income such as directors’ emoluments and certain selling and marketing and administrative expenses that have been grouped into SG&A categories on the Company’s reported consolidated financial statements, but cannot be allocated to specific business segments for purpose of calculating the segmental profit (loss) figures in accordance with HKFRS 8.

 

Bridging the Digital Divide: 5G Drives Rural Revitalization in Guangxi, China

By
Advertorial Desk
-

CHONGZUO, CHINA – Media OutReach Newswire – 26 March 2026 – In the karst terrain of Guangxi Zhuang Autonomous Region, Buhua Village, once a remote and economically underdeveloped community, has been transformed into a popular tourist attraction thanks to a 5G information superhighway co-built by China Mobile and Huawei. This digital leap has established the village as a model of rural revitalization, generating over CNY500,000 in annual collective village income and boosting per capita annual earnings by CNY18,000.

Photo-PR 1.jpg

Chongzuo is characterized by impressive karst landforms with peak clusters and peak forests. This breathtaking terrain presents huge challenges for communications network buildout. To overcome these geographic barriers, China Mobile and Huawei have collaborated on technological innovations in a bid to achieve comprehensive network coverage. Today, all administrative villages in Chongzuo have access to 5G networks, while 99% of its natural villages have 4G coverage and 94% have 5G coverage.

Buhua Village is within the jurisdiction of Chongzuo City. The village upgraded its networks from 4G to 5G as early as 2021, offering residents digital services on par with those seen in major cities. The deployment of advanced communications networks has catalyzed the growth of Buhua’s distinctive local industries.

In Xinhe Town, where the village is situated, a digital e-commerce ecosystem has been established, featuring 65 product stores on platforms like JD.com and Douyin, which are collectively owned by the village. Furthermore, a live-streaming incubation base has been established, nurturing 27 local live streamers. These stores secure over CNY300,000 in revenue each year by selling local specialties like Buhua brown sugar. This is a handcrafted product that is recognized as intangible cultural heritage, with a 150% price premium over normal brown sugar. It is sold to tier-1 cities in China, like Beijing, Shanghai, and Guangzhou, and is even exported overseas, including to Japan and South Korea.

Digital technology is also driving the upgrade of the local tourism industry. China Mobile has established an intelligent ticketing system at the Heishui River, which is Buhua Village’s most popular scenic spot where activities like rafting, boat tours, and paddleboarding are available for tourists. This system has reduced the average time for tourists to purchase tickets from 20 minutes to just 3 minutes, with online purchases now accounting for 30% of the total. Accommodation can also be booked through the system, which has increased the booking rate of local homestays by 30%.

Digitalization has further expanded to the ecological protection field. A safety monitoring and IT system project for modern irrigation engineering along the Heishui River has been launched, with investment totaling CNY100 million. Supported by the Bianjiang Zhizhou open AI platform, the digital monitoring system is set to cover 13 towns across four counties/districts in Chongzuo. Once up and running, it will enable the integrated, real-time monitoring of water quality and other ecological parameters of the Heishui River, and intelligently issue early warnings to guarantee safe water irrigation across 60,000 hectares of farmland in the river basin.

Digitalization has helped Buhua Village make the jump from poverty to prosperity. In 2025, the village’s annual collective economic income (generated from assets, land, or enterprises owned by the village community rather than individuals) exceeded CNY500,000. The average income of every household reached over CNY80,000, three times the average income from traditional sugarcane farming. The annual per capita income of villagers increased by CNY18,000. As a result, an increasing number of young people have chosen to return to the village and develop their careers.

Zhou Peng, General Manager of China Mobile Guangxi’s Chongzuo Branch, said, “By bridging the digital divide, we are helping remote villages like Buhua develop digital trade alongside traditional agriculture. This is transforming resources that were not fully used in the past due to geographical limitations into strong momentum for economic growth in the digital age.”

Tian Yongsheng, Deputy General Manager of Huawei Guangxi, noted, “Huawei is supporting China Mobile in building a solid digital foundation for Chongzuo with innovative solutions. We look forward to seeing technology overcome geographical limitations and enable more remote villages to achieve leapfrog development in the 5G and AI era.”

Hashtag: #Huawei

The issuer is solely responsible for the content of this announcement.

NYSE Content Update: Global X NYSE 100 ETF to Begin Trading Today

By
Advertorial Desk
-

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, March 26, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

IR Impact Awards took place last night

Ashley Mastronardi delivers the pre-market update on March 26th

  • Markets are down Thursday morning after Iran’s foreign minister said that the country is not currently negotiating with the U.S. to end the conflict.
  • The Global X NYSE 100 ETF launches today, with Sr. Investment Strategist Seana Smith sharing details about the offering on NYSE Live this morning.
  • POSSIBLE Global President and Co-Founder Christian Muche will join NYSE Live to discuss why next month’s event brings value to the marketing industry.
  • IR Impact’s Head of Content Steve Wade will break down the results of last night’s IR Impact Awards on NYSE Live following the Opening Bell.

Opening Bell
IR Impact celebrates the nominees and winners of the IR Impact Awards

Closing Bell
Global X ETFs launches the Global X NYSE 100 ETF (NYSE Arca: NYSX)

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

American Water celebrated 140th anniversary
American Water celebrated 140th anniversary

 

Video – https://mma.prnasia.com/media2/2943318/NYSE_Market_Update_March_26.mp4 

 

HealYou Built a Mental Health Platform for the Millions of Asians Who Would Never Use One

By
Advertorial Desk
-

Asia is rewriting mental health — and the West may not be ready for what comes next

TAIPEI and NEW YORK, March 26, 2026 /PRNewswire/ — In America, Chinese Communities Are Quietly Rewriting the Rules of Mental Health

Chinese Online Therapist
Chinese Online Therapist

For decades, the global mental health system has been shaped by a Western logic: diagnose, treat, and measure.

It is a system built on articulation — on the belief that people will name what they feel, and seek help accordingly.

That assumption is beginning to fracture.

Across Asian societies and diaspora communities, particularly among Chinese populations in the United States, a different pattern is emerging. Engagement does not begin with diagnosis. It does not always begin with therapy. In many cases, it does not begin at all — at least not in ways traditional systems recognize.

Because a quieter reality has always existed beneath the surface:

The majority of people who need help never ask for it.

The Gap No System Has Solved

According to the World Health Organization, roughly one in eight people worldwide lives with a mental health condition. Yet treatment gaps remain substantial, exceeding 70% in many regions.

Even where services are available, utilization remains uneven. Among minority communities in developed countries, the gap is often wider.

For Chinese and broader Asian populations, the barriers are not only structural, but cultural. Emotional restraint is often embedded in social norms. Disclosure is not always neutral. Seeking help can carry implications beyond the individual — extending to family, identity, and social cohesion.

As a result, demand does not disappear.
It becomes invisible.

A System Built for Those Who Speak

Modern mental health infrastructure was designed to expand access — more providers, more coverage, more awareness.

But access does not guarantee engagement.

Research published in The Lancet Psychiatry and JAMA Network Open has consistently shown that stigma, cost, and cultural mismatch continue to suppress help-seeking behavior, even in high-income settings.

Employee Assistance Programs, widely adopted across corporations, often report utilization rates below 10%.

The system has scaled.
The behavior has not.

The mismatch is no longer marginal.
It is structural.

Asia Is Not Scaling the Model — It Is Changing the Entry Point

Across Asia, a different approach is taking shape — not through policy, but through adaptation to how people actually behave.

Instead of waiting for individuals to enter formal care, these models focus on reducing the psychological threshold required to begin:

  • Access that does not require immediate disclosure
  • Services delivered in native language, not translation
  • Flexible formats that extend beyond traditional sessions
  • Support that appears before clinical recognition

Digital platforms have accelerated this shift, embedding mental health into everyday contexts rather than isolating it within clinical environments.

A Quiet Redesign, Built on Constraint

In Taiwan, platforms such as HealYou (聊心茶室) have developed cross-border mental health networks that connect users with licensed professionals, while adapting services to linguistic and cultural realities.

They operate within one of Asia’s more tightly regulated professional environments, where psychologists are required to complete formal clinical training and national certification. The regulatory structure imposes a level of rigor that shapes both supply and trust.

At the same time, the platform is built primarily around Traditional Chinese — a linguistic system that demands not only fluency, but precision in meaning, tone, and cultural reference across different Chinese-speaking communities.

Within that constraint lies its design logic:

If people will not enter the system as it exists, the system must change how it meets them.

Not at the point of crisis.
But earlier — where hesitation still outweighs resistance.

The Market No One Sees

The global mental health market is projected to expand significantly in the coming decade.

But most forecasts are based on a familiar premise: that more people will enter existing systems.

The more consequential question may be different:

What about those who never will?

Asia, which represents more than half of the world’s population, remains unevenly served by culturally aligned mental health infrastructure. At the same time, high digital adoption and shifting generational attitudes are enabling new forms of engagement.

This creates a paradox.

The regions with the lowest historical participation may become the fastest-growing — not because they are catching up, but because they are building from different assumptions.

What Comes Next

If the last century defined mental health through clinical authority, and the last decade expanded access through technology, the next phase may be defined by something less visible:

Alignment.

Not every system scales globally.
But systems that align with behavior often scale faster.

The question is no longer whether mental health will grow.
It already is.

The question is who defines how it works.

And increasingly, that answer may not come from where the model was first built —
but from where it never fully applied.

CONTACT: Jessie Chang, support@healyou.io

GSCF Launches C4: Connected Capital Control Center

By
Advertorial Desk
-

Delivering Visibility and Control to Corporates, Banks & Asset Managers

NEW YORK, March 26, 2026 /PRNewswire/ — GSCF, a leading global provider of working capital solutions, today announced the launch of Connected Capital Control Center (C4) – a servicing platform designed to help banks, asset managers and enterprise corporates originate, manage and analyze working capital with greater visibility, control and confidence across multiple programs.

Built to support GSCF’s Connected Capital ecosystem and the broader market landscape, C4 addresses a growing market need: organizations are deploying multiple working capital programs across regions, funders, insurers and service providers, yet lack a single source of truth to track exposure, liquidity, cost and risk across their entire portfolio of programs.

C4 consolidates program data and workflows into one unified control layer for programs serviced by GSCF or external providers, enabling financial institutions and enterprises to scale working capital more efficiently while reducing operational friction and risk.

“As working capital portfolios grow more complex, fragmented views and manual oversight aren’t sustainable,” said Doug Morgan, Chief Executive Officer of GSCF. “C4 brings portfolio-level clarity to enterprises and their funding partners – so decisions can be made with confidence, limits can be enforced proactively, and working capital can be deployed more strategically across the global ecosystem.”

C4 for Enterprise Corporates: Advanced Intelligence for the Office of the CFO

For global enterprises relying on multiple working capital programs across regions, funders and administrators to drive liquidity and fuel growth, C4 provides a single, aggregated view of all working capital activity to eliminate data silos and enable centralized oversight.

Key capabilities for corporates include:

  • Aggregated Data Views: A single source of truth consolidating all working capital programs, regardless of funder or platform
  • Portfolio-Level Intelligence: Holistic visibility across regions, buyers, suppliers and counterparties to support CFO- and Treasurer-level decisioning
  • Cross-Funder Transparency: Clear insight into funding flows, utilization and pricing across multiple banks and capital partners
  • Global Operational Workflows: Standardized and automated processes designed for multi-region, multi-funder environments
  • Exposure and Concentration Management: Program- and portfolio-level analytics to identify risk, adjust limits and optimize capital allocation

By unifying data and decisioning at the portfolio level, C4 allows enterprises to move beyond reactive reporting and manage working capital as a strategic asset.

C4 for Banks: Scaling Working Capital with Confidence and Control

For trade finance and structured working capital teams, C4 delivers real-time visibility and embedded controls across multi-program and multi-funder portfolios to enable faster origination, stronger governance and scalable growth.

Key capabilities for banks include:

  • Portfolio-Level Visibility: A consolidated, real-time view of exposure across obligors, regions, insurers and structures
  • Built-In Limit Management: Embedded credit limits, concentration thresholds, alerts and automated “pause” mechanisms
  • Streamlined Accounts Receivable: Standardized AR processes that scale from simple programs to complex, insured structures
  • Co-Origination and Extended Capacity: A unique combination of servicing expertise and funding capabilities that expands balance-sheet flexibility

C4 empowers banks to shift from a model of program-by-program oversight to true portfolio management, reducing blind spots while increasing confidence in the ability to grow with efficiency and discipline.

A Control Center Built for Scale, Not Silos

Unlike today’s working capital landscape that can be fragmented across operations, technology and data, C4 is designed as a portfolio-level control layer that integrates technology with GSCF’s world-class managed services. Backed by more than 30 years of experience operating complex working capital programs globally, GSCF embeds operational precision directly into the platform – allowing clients to offload complexity while fully retaining control.

“C4 addresses the needs of banks and enterprises today while supporting their growth across multiple programs, partners and jurisdictions,” said Shannon Dolan, Chief Product Officer of GSCF. “By consolidating data, limits, workflows and decisioning into one control center, C4 will help teams act faster, reduce risk and continuously optimize working capital performance at scale.”

“The evolution of working capital management is moving beyond process efficiency toward liquidity orchestration. As enterprises and their financial partners deploy programs across an increasingly complex ecosystem of funders, regions and structures, the demand for portfolio-level visibility and control is intensifying. C4 reflects where the market is heading – a unified control layer that enables CFOs and Treasurers to manage liquidity not just as an operational necessity, but as a driver of business performance and resilience,” said Senior Research Director, IDC Enterprise Applications, Kevin Permenter.

About GSCF

GSCF is the leading global provider of working capital solutions. The Company enables corporates and financial partners to accelerate growth, unlock liquidity and manage the risk and complexity of the end-to-end working capital cycle. We originate, manage and analyze working capital programs through our innovative Working Capital as a Service offering, combining the power of a configurable and comprehensive technology platform, expert services and a Connected Capital ecosystem of alternative capital solutions and bank capital. GSCF’s team of working capital experts operates in over 75 countries to solve global working capital efficiency challenges. Visit www.gscf.com to learn more.

Media Contact:
Natalie Silverman
Chief Marketing Officer at GSCF
natalie.silverman@gscf.com 

Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer’s Disease Therapies

By
Advertorial Desk
-
  • Aims to improve quality of care for patients with Alzheimer’s disease… Exploring adoption of Neurophet’s key solutions
  • Collaboration expected to leverage Neurophet AQUA, Neurophet SCALE PET and Neurophet AQUA AD Plus

SEOUL, South Korea, March 26, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a memorandum of understanding (MOU) with the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET).

Neurophet Signs MOU with ALZ-NET
Neurophet Signs MOU with ALZ-NET

The agreement aims to support healthcare professionals participating in ALZ-NET and enhance the quality of care for patients with Alzheimer’s disease. Under the partnership, the two parties will work to raise awareness of the importance of monitoring Amyloid-Related Imaging Abnormalities (ARIA), while also providing discounted access to Neurophet’s key solutions across medical institutions participating in ALZ-NET and expanding their clinical utilization.

The collaboration will involve Neurophet’s flagship solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software; Neurophet SCALE PET, a quantitative Positron Emission Tomography (PET) imaging analysis software; Neurophet AQUA AD Plus, an integrated brain imaging analysis solution designed to support treatment decision-making for Alzheimer’s disease therapies.

Neurophet AQUA, Neurophet SCALE PET, and Neurophet AQUA AD Plus have each received 510(k) clearance from the U.S. Food and Drug Administration (FDA). A number of Alzheimer’s disease treatment medical centers and neuroimaging facilities participating in ALZ-NET are expected to leverage Neurophet’s key solutions going forward.

Sponsored by the Alzheimer’s Association and managed and operated by the American College of Radiology (ACR), ALZ-NET is an Alzheimer’s treatment and diagnostics network that collects and analyzes clinical and imaging data from patients receiving novel FDA-approved Alzheimer’s therapies through voluntarily participating medical institutions. Through these efforts, ALZ-NET supports the advancement of clinical evidence and the standardization of care in the field of Alzheimer’s treatment and diagnostics.

Ana Franceschi, MD, PhD, Chair of the ACR Neuroradiology Research Committee and member of the ALZ-NET Imaging Workgroup, stated, “We are pleased to collaborate with Neurophet to bring their innovative imaging solution to ALZ-NET sites. Strengthening imaging infrastructure across the network is essential to providing high-quality care as Alzheimer’s treatment continues to advance.”

Jake Junkil Been, Co-CEO of Neurophet, said, “With ALZ-NET, Neurophet aims to contribute the establishment of an imaging-based monitoring infrastructure that is essential in the era of Alzheimer’s therapies. We will contribute to enhance the overall quality of the Alzheimer’s treatment ecosystem in the United States.”

About Neurophet

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software “Neurophet AQUA”, PET Image Quantitative Analysis Software “Neurophet SCALE PET”, Brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”, Alzheimer’s Disease treatment prescription and monitoring software “Neurophet AQUA AD” for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software “Neurophet AQUA MS”.

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.

The Pinkfong Company Introduces AI Voice-Powered Fan Creation for New IP “REDREX”

By
Advertorial Desk
-
  • Partners with HYBE’s Supertone to enable fan-created content using REDREX AI voices
  • Surpassed 500K followers and 21M TikTok views since its October 2025 debut

SEOUL, South Korea, March 26, 2026 /PRNewswire/ — The Pinkfong Company, the global entertainment company behind Baby Shark, today announced a collaboration with HYBE’s AI voice technology company Supertone to expand fan-driven content creation for its new IP, REDREX.

The Pinkfong Company Introduces AI Voice-Powered Fan Creation for New IP “REDREX”
The Pinkfong Company Introduces AI Voice-Powered Fan Creation for New IP “REDREX”

Through the partnership, official character voices from REDREX will be available on Supertone Play, Supertone’s AI voice creation platform. By making character-based text-to-speech (TTS) voices, the companies aim to enable fans to create memes, dubbed videos, and other short-form content using REDREX character voices.

REDREX is a short-form animated office comedy designed for social platforms. The series centers on Rex, a “workaphobic” dinosaur who seems to be allergic to work — especially Mondays. Each episode runs approximately one to three minutes and humorously captures the ups and downs of office life. The series resonates with Gen Z and millennials navigating the humor and challenges of modern workplace culture.

As part of the collaboration, Supertone Play will leverage its advanced voice models, including Sona Speech 1 and Sona Speech 2, which support 23 languages and deliver highly expressive, natural-sounding performances. Supertone is an AI audio technology company whose technology has been used in productions on major streaming platforms. The company develops hyper-realistic voices capable of both acting and singing, empowering creators to craft more immersive and engaging content.

Since its initial release on social media in October 2025, REDREX has quickly gained traction online. The brand’s social channels have surpassed 500,000 followers, while TikTok videos have generated more than 21 million views, with particularly strong engagement from audiences in North America. New episodes are released every Sunday on the official REDREX YouTube channel.

“REDREX has gained strong traction in North America since its debut on social media,” said Bitna Kwon, Chief Strategy Officer at The Pinkfong Company. “Through our partnership with Supertone, we hope to introduce REDREX to even more fans and unlock new forms of fan-created content powered by AI voice technology.”

Download images here

About The Pinkfong Company
The Pinkfong Company is a global entertainment company that delivers content and entertaining experiences around the world. Driven by award-winning brands and IPs, the company has created and distributed a range of content across genres and formats including original animated series, world live tours, interactive games, and more. Believing in the power of entertaining and engaging content, The Pinkfong Company is committed to connecting people around the world and bringing joy and inspiration to worldwide audiences of all ages. For more information, please visit the website or follow the company on LinkedIn.

Media Contact
Hailey Kim
Communications Manager
The Pinkfong Company
hailey@pinkfong.com

1...757758759...6,557Page 758 of 6,557